Last10K.com

Aptevo Therapeutics Inc. (APVO) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

APVO Annual Reports

    10-K Annual Report March 2022
    10-K Annual Report March 2021
  • 10-K Annual Report March 2020
  • 10-K Annual Report March 2019
    10-K Annual Report March 2018
    10-K Annual Report March 2017

Aptevo Therapeutics Inc.

CIK: 1671584 Ticker: APVO
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Mar. 25, 2020
Jun. 30, 2019
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2019  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  
Trading SymbolAPVO  
Entity Registrant NameAPTEVO THERAPEUTICS INC.  
Entity Central Index Key0001671584  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryNon-accelerated Filer  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Interactive Data CurrentYes  
Entity Shell Companyfalse  
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Extended Transition Periodtrue  
Entity Common Stock, Shares Outstanding 45,279,244 
Entity Public Float  $ 36.6
Title of 12(b) SecurityCommon Stock, $0.001 par value per share  
Security Exchange NameNASDAQ  
Entity File Number001-37746  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number81-1567056  
Entity Address, Address Line One2401 4th Avenue  
Entity Address, Address Line TwoSuite 1050  
Entity Address, City or TownSeattle  
Entity Address, State or ProvinceWA  
Entity Address, Postal Zip Code98121  
City Area Code206  
Local Phone Number838-0500  
Document Annual Reporttrue  
Document Transition Reportfalse  
Documents Incorporated by Reference

Portions of the Registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, relating to the Registrant’s 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report.

  

View differences made from one year to another to evaluate Aptevo Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aptevo Therapeutics Inc..

Continue

Assess how Aptevo Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aptevo Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
Other
Filter by Subcategory:
All
Geography
Product
Expense
Shares
Cash Flow
Debt
Income
Other
Inside Aptevo Therapeutics Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
401(K) Savings Plan
401(K) Savings Plan - Additional Information (Details)
Cash, Cash Equivalents, And Restricted Cash
Cash, Cash Equivalents, And Restricted Cash (Tables)
Cash, Cash Equivalents, And Restricted Cash - Additional Information (Details)
Cash, Cash Equivalents, And Restricted Cash - Schedule Of Cash, Cash Equivalents And Restricted Cash, Both Current And Long-Term Portion (Details)
Collaboration Agreements
Collaboration Agreements - Additional Information (Details)
Debt
Debt - Additional Information (Details)
Discontinued Operations - Milestone Payment - Additional Information (Details)
Discontinued Operations ??? Milestone Payment
Equity
Equity (Tables)
Equity - Additional Information (Details)
Equity - Assumptions Used In Valuing The Stock Options Granted Under Black-Scholes Valuation Model (Details)
Equity - Summary Of Restricted Stock Activity (Details)
Equity - Summary Of Stock Option Activity (Details)
Equity - Summary Of Stock-Based Compensation Expense Includes Amortization Of Stock Options And Restricted Stock Units Granted (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Details)
Fair Value Measurements - Summary Of Financial Assets Measured At Fair Value (Details)
Fair Value Measurements - Summary Of Financial Assets Measured At Fair Value (Parenthetical) (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Loss From Continuing Operations Before Income Taxes (Details)
Income Taxes - Schedule Of Reconciliation Of Federal Statutory Income Tax Rate To Effective Income Tax From Continuing Operations (Details)
Income Taxes - Schedule Of Tax Effects Of Temporary Differences Give Rise To Significant Portions Of Deferred Tax Assets And Deferred Tax Liabilities (Details)
Intangible Assets, Net
Intangible Assets, Net (Tables)
Intangible Assets, Net - Additional Information (Details)
Intangible Assets, Net - Schedule Of Future Amortization Expense (Details)
Inventories
Inventories (Tables)
Inventories - Schedule Of Inventories (Details)
Investments
Investments (Tables)
Investments - Schedule Of Short-Term Investments (Details)
Investments - Schedule Of Short-Term Investments (Parenthetical) (Details)
Leases And Contingencies
Leases And Contingencies (Tables)
Leases And Contingencies - Additional Information (Details)
Leases And Contingencies - Components Of Lease Expense (Details)
Leases And Contingencies - Summary Of Future Minimum Lease Payments (Details)
Leases And Contingencies - Summary Of Right Of Use Assets Acquired Under Operating Leases (Details)
Nature Of Business And Significant Accounting Policies
Nature Of Business And Significant Accounting Policies (Policies)
Nature Of Business And Significant Accounting Policies (Tables)
Nature Of Business And Significant Accounting Policies - Additional Information (Details)
Nature Of Business And Significant Accounting Policies - Schedule Of Estimated Useful Lives Of Property And Equipment (Details)
Nature Of Business And Significant Accounting Policies - Schedule Of Major Customers Concentration Risk Percentage (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Additional Information (Details)
Net Loss Per Share - Computation Of Basic And Diluted Net Loss Per Share (Details)
Net Loss Per Share - Summary Of Potentially Dilutive Shares Excluded From Calculation Of Net Loss Per Share (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Details)
Property And Equipment, Net - Summary Of Property And Equipment (Details)
Revenue Reserves
Revenue Reserves (Tables)
Revenue Reserves - Summary Of Receivable Related Allowances And Revenue Related Liabilities (Details)
Subsequent Events
Subsequent Events - Additional Information (Details)
Ticker: APVO
CIK: 1671584
Form Type: 10-K Annual Report
Accession Number: 0001564590-20-012791
Submitted to the SEC: Wed Mar 25 2020 3:22:31 PM EST
Accepted by the SEC: Wed Mar 25 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/apvo/0001564590-20-012791.htm